Stocks and Investing Stocks and Investing
Fri, December 21, 2018
Thu, December 20, 2018
Wed, December 19, 2018

Matthew Harrison Maintained (UBX) at Buy with Decreased Target to $240 on, Dec 19th, 2018


Published on 2024-10-26 11:21:47 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Unity Biotechnology, Inc." (UBX) at Buy with Decreased Target from $250 to $240 on, Dec 19th, 2018.

Matthew has made no other calls on UBX in the last 4 months.



There is 1 other peer that has a rating on UBX. Out of the 1 peers that are also analyzing UBX, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Salim Syed of "Mizuho" Initiated at Strong Buy and Held Target at $330 on, Friday, September 7th, 2018

Contributing Sources